Rose Hill and The Canadian Center for Psychedelic Science in Partnership
Founded in 2018, The Canadian Centre for Psychedelic Science
established the Psychedelic Science Research Program at the
University of Toronto, and, more recently, played a central role in
founding the International Consortium for Psychedelic Research
Centers. Currently running one of the first clinical trials examining
the impact of micro dosing psilocybin on Major Depressive Disorder.
Rose Hill has formed a partnership with the Canadian Center for Psychedelic Science. This collaboration seeks to merge the latest research with practical therapeutic methods. Dedicated to enhancing mental health care, the center’s approach is rooted in rigorous scientific research. Their goal is to develop safe and effective treatment methods, ushering in a new chapter in mental health treatment
Phase 1
This protocol is for a randomized, placebo-controlled
crossover phase 1 study of the safety and efficacy of low doses of psilocybin in healthy subjects with depressive symptoms who meet DSM-5 criteria for diagnosis of a mild to moderate Major Depressive Disorder (MDD ) and who are either unwilling to pursue standard treatment (psychotherapy and/or pharmacotherapy) or have previously been non-responsive to standard treatment.
This feasibility study will assess
whether microdosing has a short-term impact on participant ratings of depressive symptoms.
Phase 2
We are now recruiting participants who wish to join the next step of our work. This effort continues our partnership with the Canadian Center for Psychedelic Science. We aim to see how low-dose psilocybin might support those who struggle with depression.